KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Notes Payables: 2009-2017

Historic Notes Payables for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Dec 2017 value amounting to $1.0 million.

  • Teva Pharmaceutical Industries' Notes Payables fell 93.33% to $1.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.0 million, marking a year-over-year decrease of 93.33%. This contributed to the annual value of $1.0 million for FY2017, which is 93.33% down from last year.
  • As of Q4 2017, Teva Pharmaceutical Industries' Notes Payables stood at $1.0 million, which was down 93.33% from $15.0 million recorded in Q4 2016.
  • Teva Pharmaceutical Industries' Notes Payables' 5-year high stood at $23.0 billion during Q2 2015, with a 5-year trough of $1.0 million in Q4 2017.
  • Its 3-year average for Notes Payables is $11.4 billion, with a median of $11.4 billion in 2015.
  • Examining YoY changes over the last 5 years, Teva Pharmaceutical Industries' Notes Payables showed a top increase of 2,583.06% in 2014 and a maximum decrease of 94.59% in 2014.
  • Over the past 5 years, Teva Pharmaceutical Industries' Notes Payables (Quarterly) stood at $850.0 million in 2013, then plummeted by 94.59% to $46.0 million in 2014, then surged by 63.04% to $75.0 million in 2015, then plummeted by 80.00% to $15.0 million in 2016, then crashed by 93.33% to $1.0 million in 2017.
  • Its Notes Payables stands at $1.0 million for Q4 2017, versus $15.0 million for Q4 2016 and $75.0 million for Q4 2015.